

High-Density Lipoproteins

From Basic Biology to Clinical Aspects

Edited by
Christopher J. Fielding



WILEY-VCH Verlag GmbH & Co. KGaA

Contents

Preface XV

List of Contributors XVII

I HDL Structure 1

1 Apolipoprotein A-I Structure 3

Michael N. Oda, Robert O. Ryan

- 1.1 Introduction and Perspective 3
- 1.2 Lipid-Free ApoA-I 3
- 1.3 The Role of Protein Structure in ApoA-I Function 4
- 1.4 Full-Length ApoA-I X-Ray Structure 9
- 1.5 Apolipoprotein A-I Structure – Lipid-Bound State 11
- 1.6 Structural Studies of ApoA-I on Discoidal Nascent HDL 12
- 1.7 Hinge Domain 14
- 1.8 Computer Models 15
- 1.9 Spherical HDL 16
- 1.10 Future Directions 16
- 1.11 Acknowledgments 16

2 Apolipoprotein A-II 25

Joan Carles Escolà-Gil, Jesús M. Martín-Campos, Josep Julve, Francisco Blanco-Vaca

- 2.1 Apolipoprotein A-II Structure and Plasma Level Regulation 25
 - 2.1.1 Structural Organization and Transcriptional Regulation of the Gene 25
 - 2.1.2 ApoA-II Mutations and Polymorphisms 27
 - 2.1.3 Protein Structure, Synthesis, Secretion, and Metabolism 28
 - 2.1.4 Other Determinants of ApoA-II Levels 33
- 2.2 Pathophysiological Role of ApoA-II 33
 - 2.2.1 On HDL Metabolism 33

2.2.1.1	HDL Remodeling	33
2.2.1.2	Reverse Cholesterol Transport Function	35
2.2.1.3	Antioxidant and Anti-inflammatory Effects	36
2.2.2	Role of ApoA-II in Triglyceride and Glucose Metabolism	37
2.2.2.1	Triglyceride and Free Fatty Acid (FFA) Metabolism	37
2.2.2.2	Glucose Homeostasis	38
2.2.2.3	Role of ApoA-II in Dyslipidemia and Type 2 Diabetes Mellitus	38
2.2.3	ApoA-II in Atherogenesis	41
2.3	Acknowledgments	41
3	Apolipoprotein E and Reverse Cholesterol Transport: The Role of Recycling in Plasma and Intracellular Lipid Trafficking	55
	<i>Larry L. Swift, Alyssa H. Hasty, MacRae F. Linton, Sergio Fazio</i>	
3.1	Introduction	55
3.2	Role of ApoE in Triglyceride-Rich Lipoprotein Metabolism	56
3.2.1	ApoE and Lipoprotein Assembly and Secretion	56
3.2.2	ApoE and Lipoprotein Processing and Catabolism	58
3.2.3	ApoE and Lipoprotein Uptake	58
3.3	Role of ApoE in HDL Metabolism	60
3.3.1	HDL Formation and Maturation	60
3.3.2	Cholesterol Efflux and RCT	62
3.3.3	Roles of apoE in RCT and HDL Metabolism	63
3.3.4	Critical Roles for ApoE and SR-BI in RCT	65
3.4	ApoE and Recycling	66
3.4.1	Evidence for apoE Recycling	66
3.4.2	Regulation of ApoE recycling	70
3.4.3	ApoE Recycling and Cholesterol Efflux	71
3.4.4	Form of Recycled ApoE	72
3.4.5	ApoE Recycling: Relevance to Atherosclerosis	73
3.5	Summary	74
4	ApoM – A Novel Apolipoprotein with Antiatherogenic Properties	89
	<i>Ning Xu, Peter Nilsson-Ehle</i>	
4.1	Introduction	89
4.2	Cloning and Characterization of Human ApoM	90
4.3	Gene Location and Amino Acid Sequence of ApoM	91
4.4	Protein Structure of ApoM	93
4.5	Distribution of ApoM in Plasma Lipoproteins	94
4.6	Tissue Distribution and Cellular Expression of ApoM	95
4.7	Putative Functions of ApoM	97
4.8	Regulation of ApoM	99
4.9	Hormonal Regulation of ApoM	102
4.10	Clinical Observations	104
4.11	Conclusions and Perspectives	105

II	HDL Plasma Metabolic Factors	111
5	ATP Binding Cassette Transporters	113
	<i>Laetitia Dufort, Giovanna Chimini</i>	
5.1	The Family of ABC Transporters – General Features	113
5.2	ABC Transporters and Lipid Transport	118
5.3	The ABCA Subfamily and the Handling of Excess Lipids	119
5.3.1	ABCA1	121
5.3.1.1	ABCA1 Expression and its Control	121
5.3.1.2	Structural Considerations	123
5.3.1.3	ABCA1 and Cellular Effluxes of Phospholipid and Cholesterol – Facts and Speculation	124
5.3.2	ABCA7	126
5.3.2.1	From the Gene to the Protein	126
5.3.2.2	The ABCA7 Knockout Mouse – A Model with some Surprises	127
5.4	The ABCG Subfamily and Sterol Trafficking	128
5.4.1	ABCG1	129
5.4.1.1	Expression and its Regulation	129
5.4.1.2	Physiopathology and Functional Predictions	130
5.5	Acknowledgments	131
6	Reverse Cholesterol Transport – New Roles for Preβ₁-HDL and Lecithin:Cholesterol Acyltransferase	143
	<i>Christopher J. Fielding, Phoebe E. Fielding</i>	
6.1	Introduction	143
6.2	Structure and Properties of Pre β ₁ -HDL	144
6.3	Cell Membrane Origin of FC for RCT	146
6.4	Role of ABCA1 in FC Transfer	147
6.5	Mechanism of Lecithin:Cholesterol Acyltransferase (LCAT)	149
6.6	Origins of FC and PL for LCAT Activity	150
6.7	Further Metabolism of LCAT/Pre β ₁ -HDL Complexes	152
6.8	ApoA-1 Recycling and the Production of Pre β ₁ -HDL	154
6.9	Revised Model of RCT	155
7	HDL Remodeling by CETP and SR-BI	163
	<i>Christopher J. Harder, Ruth McPherson</i>	
7.1	Introduction	163
7.2	Atheroprotective Function of HDL	163
7.3	Cholesteryl Ester Transfer Protein (CETP)	164
7.4	Selective Uptake	164
7.5	SR-BI Function and Trafficking in Hepatocytes	165
7.6	Cellular Mechanisms of SR-BI-Mediated Biliary Cholesterol Secretion	170

7.7	Role of CETP in Direct Clearance of HDL-derived CE (Selective Uptake) 170
7.8	Summary 173
8	Human Plasma Phospholipid Transfer Protein (PLTP) – Structural and Functional Features 183 <i>Sarah Siggins, Kerry-Ann Rye, Vesa M. Olkkonen, Matti Jauhiainen, Christian Ehnholm</i>
8.1	Introduction 183
8.2	Lipid Transfer Proteins 184
8.3	Phospholipid Transfer Protein (PLTP) 184
8.3.1	Characteristics of PLTP 184
8.3.2	Regulation of PLTP Gene Expression 186
8.4	Functions of PLTP 187
8.4.1	Phospholipid Transfer Activity 187
8.4.2	HDL Remodeling 189
8.4.3	Cellular Cholesterol Efflux 190
8.4.4	PLTP in Human Plasma and Tissues 190
8.4.5	Low-Activity (LA) and High-Activity (HA) PLTP 192
8.5	PLTP and Atherosclerosis 193
8.5.1	Insights from Mouse Models 193
9	Use of Gene Transfer to Study HDL Remodeling 207 <i>Kazuhiro Oka, Lawrence Chan</i>
9.1	Introduction 207
9.2	Vectors for Gene Transfer 208
9.2.1	Physical Delivery of Nonviral DNA 208
9.2.2	Nonviral Vectors 209
9.2.2.1	Phage Integrase 209
9.2.2.2	Adeno-Associated Virus (AAV) Rep Protein-Mediated Integration 209
9.2.3	Viral Vectors 210
9.2.3.1	DNA Viral Vectors 210
9.2.3.2	RNA Viral Vectors 213
9.3	Roles of Lipases and HDL-Associated Enzymes in HDL Remodeling 214
9.3.1	Endothelial Lipase (EL) 214
9.3.2	Hepatic Lipase (HL) 216
9.3.3	Lipoprotein Lipase (LPL) 217
9.3.4	Structural and Functional Alterations of HDL by Enzymes 218
9.3.5	Paraoxonases (PONs) 218
9.3.6	Myeloperoxidase (MPO) 219
9.4	Conclusion 220
9.5	Perspective 220
9.6	Acknowledgments 221

III	HDL Formation, Secretion, Removal	235
10	Regulation of Genes Involved in the Biogenesis and the Remodeling of HDL	237
	<i>Dimitris Kardassis, Costas Drosatos, and Vassilis I. Zannis</i>	
10.1	Introduction	237
10.2	The Coregulator Complexes	237
10.2.1	Nuclear Hormone Receptors	239
10.2.2	LXR, FXR, LRH-1, SHP	240
10.2.3	PPAR α , - β , - γ	240
10.2.4	SF-1	240
10.2.5	HNF-4	240
10.2.6	ARP-1, EAR-3	241
10.2.7	SP1 Family of Proteins	241
10.2.8	SREBPs	241
10.3	Transcriptional Regulation of Genes Involved in HDL Biogenesis and Catabolism	242
10.3.1	Transcriptional Regulation of the Human ApoA-I Gene	242
10.3.1.1	<i>In vitro</i> Studies	242
10.3.1.2	<i>In vivo</i> Studies	244
10.3.1.3	Putative Mechanisms of ApoA-I Gene Transcription	245
10.3.1.4	<i>In vivo</i> Regulation of the ApoA-I Gene in Transgenic and Knockout Animal Models, as well as in Response to Pharmacological and Dietary Treatments	247
10.3.2	Transcriptional Regulation of the ABCA1 Gene	248
10.3.3	Transcriptional Regulation of the ABCG1 Gene	249
10.3.4	Transcriptional Regulation of the SR-BI Gene	251
10.3.5	Transcriptional Regulation of the CETP Gene	252
10.3.6	Transcriptional Regulation of the PLTP Gene	252
10.4	Conclusions	253
10.5	Acknowledgements	253
11	ApoA-I Functions and Synthesis of HDL: Insights from Mouse Models of Human HDL Metabolism	267
	<i>Vassilis I. Zannis, Eleni E. Zanni, Angeliki Papapanagiotou, Dimitris Kardassis, Christopher J. Fielding, Angeliki Chroni</i>	
11.1	Structures of ApoA-I and High-Density Lipoprotein (HDL)	267
11.2	ApoA-I Participates in the Biogenesis and Catabolism of HDL and Interacts with Several Other Proteins of the HDL Pathway	269
11.3	Functional Interactions between Lipid-Free ApoA-I and the ABCA1 Lipid Transporter Represent the First Step in the Biogenesis of HDL	270
11.3.1	<i>In vitro</i> Analysis of the Interactions between ApoA-I and ABCA1 that Lead to Cholesterol and Phospholipid Efflux through the Use of Targeted ApoA-I Mutations	270

- 11.3.2 Use of Adenovirus-Mediated Gene Transfer to Study how ApoA-I Mutations Affect the Biogenesis of HDL 274
- 11.4 ApoA-I/ABCA1 Interactions: Intracellular Trafficking of the Complex 279
- 11.5 Contribution of the HDL Pathway in the Reverse Transport of Cholesterol 279
- 11.6 HDL Biogenesis can be Inhibited by Specific Mutations in ApoA-I that Inhibit Activation of LCAT 281
- 11.7 Mutations in ApoA-I may Induce Hypertriglyceridemia and Other Dyslipidemias 283
- 11.8 Remodeling of the HDL Particles after Interactions between HDL-Bound ApoA-I and SR-BI 284
- 11.9 Remodeling of HDL Particles after Interactions with ABCG1 287
- 11.10 The Downstream Steps of the HDL Pathway 288
- 11.11 Origins and Functions of HDL Subpopulations 288
- 11.11.1 *De novo* Synthesis of Pre β HDL 288
- 11.11.2 Generation of Pre β 1 HDL from α HDL Particles 290
- 11.12 Importance of HDL Subpopulations 291
- 11.13 Role of ApoA-I and HDL in Atheroprotection 291
- 11.14 Conclusions 292
- 11.15 Acknowledgments 293

- 12 Hepatic and Renal HDL Receptors 307**
Laurent O. Martinez, Bertrand Perret, Ronald Barbaras, François Tercé, Xavier Collet
- 12.1 Historical Background 307
- 12.1.1 HDL Receptors: From Myth to Reality 307
- 12.1.2 To be or not to be an HDL Receptor? 308
- 12.2 SR-BI-Mediated Selective HDL Cholesterol Uptake 310
- 12.2.1 The Selective HDL Cholesteryl Ester Uptake Pathway 310
- 12.2.2 SR-BI as a Receptor for Selective Lipoprotein Cholesterol Uptake 311
- 12.2.3 Role of Hepatic SR-BI in Murine Cholesterol Homeostasis and Atherogenesis 311
- 12.2.4 Regulation of Hepatic SR-BI 312
- 12.2.5 Mechanism of SR-BI-Mediated Selective Lipoprotein Cholesterol Uptake 314
- 12.3 Ecto-F₁-ATPase: An Unexpected Role in HDL Endocytosis 316
- 12.3.1 Two HDL Binding Sites Allocated to One HDL Endocytosis Pathway 316
- 12.3.2 Ecto-F₁-ATPase as a High-Affinity ApoA-I Receptor 317
- 12.3.3 The Ecto-F₁-ATPase/P2Y₁₃-Mediated HDL Endocytosis Pathway 319
- 12.3.4 Extracellular ADP Levels as a Crucial Point of Regulation of HDL Endocytosis 319
- 12.3.5 F₁-ATPase as a Moonlighting Protein Complex 320

12.3.6	The Checkpoints for Regulation of the F ₁ -ATPase-Mediated HDL Endocytosis Pathway	322
12.4	Others Receptors involved in HDL Metabolism	323
12.4.1	Contribution of ABCA1 to Hepatic ApoA-I Secretion	323
12.4.2	The Role of Cubilin in Renal ApoA-I Catabolism	324
12.5	Relevance to Human Physiopathology	325
IV	Biological Activities of HDL	339
13	HDL and Inflammation	341
	<i>Mohamad Navab, Srinivasa T. Reddy, Brian J. Van Lenten, Georgette M. Buga, G. M. Anantharamaiah, Alan M. Fogelman</i>	
13.1	HDL as Part of the Innate Immune System	341
13.2	The Role of Oxidized Phospholipids and HDL-Associated Enzymes	342
13.3	A Connection between Reverse Cholesterol Transport and Inflammation	343
13.4	The Inflammatory Properties of HDL in Humans	344
13.5	Oxidative Stress and Inflammation	345
13.6	Apolipoprotein Mimetic Peptides that Modulate HDL Function	346
13.7	Summary	350
13.8	Acknowledgments	350
14	HDL in Health and Disease: Effects of Exercise and HIV Infection on HDL Metabolism	355
	<i>Dmitri Sviridov, Michael I. Bukrinsky, Bronwyn A. Kingwell, Jennifer Hoy</i>	
14.1	Introduction	355
14.2	HDL Metabolism	356
14.2.1	HDL Formation	356
14.2.2	HDL Maturation	356
14.2.3	HDL Remodeling	357
14.2.4	Efficiency of Reverse Cholesterol Transport	357
14.3	Exercise and HDL Metabolism	360
14.3.1	HDL Formation	360
14.3.2	HDL Maturation	361
14.3.3	HDL Remodeling	361
14.3.4	Exercise and the Efficiency of Reverse Cholesterol Transport	362
14.4	HIV Infection and HDL Metabolism	362
14.4.1	HDL Formation	363
14.4.2	HDL Maturation	363
14.4.3	HDL Remodeling	364
14.4.4	HIV Infection and the Efficiency of Reverse Cholesterol Transport	364
14.5	Fixing HDL Metabolism	366

15	Endothelial Protection by High-Density Lipoproteins	375
	<i>Monica Gomaschi, Laura Calabresi, Guido Franceschini</i>	
15.1	Endothelial Dysfunction and Cardiovascular Disease	375
15.2	HDL and Regulation of Vascular Tone	377
15.2.1	Nitric Oxide	377
15.2.2	Prostacyclin	380
15.3	HDL and Vascular Inflammation	381
15.3.1	Cellular Adhesion Molecules	381
15.3.2	Cytokines	383
15.3.3	Platelet-Activating Factor	384
15.4	HDL and Hemostasis	384
15.4.1	Platelet Adhesion and Reactivity	384
15.4.2	Coagulation	385
15.4.3	Fibrinolysis	386
15.5	HDL and Endothelial Monolayer Integrity	386
15.5.1	Endothelial Cell Apoptosis	386
15.5.2	Migration and Proliferation of Endothelial Cells	387
15.6	Conclusions and Perspectives	388
16	The Effect of Nutrients on Apolipoprotein A-I Gene Expression	399
	<i>Arshag D. Mooradian</i>	
16.1	Introduction	399
16.2	Effect of Caloric Intake	400
16.3	Effects of Various Nutrients on HDLc and ApoA-I	400
16.3.1	Effects of Lipids	400
16.3.1.1	Effect of Fatty Acid Saturation	403
16.3.1.2	Effects of Oxidized Fatty Acids	406
16.3.1.3	Effect of <i>trans</i> -Fatty Acids	407
16.3.1.4	Effects of Medium-Chain Fatty Acids	408
16.3.1.5	Effects of ω -3-Fatty Acids	408
16.3.1.6	Effect of Fat Metabolites: Ketones and Prostanoids	409
16.4	Effects of Carbohydrates or their Metabolites	410
16.4.1	Effect of Glucose	410
16.4.2	Effects of Fructose	411
16.4.3	Effect of Glucosamine	411
16.5	Effects of Protein	412
16.6	Effects of Micronutrients	412
16.7	Effects of Alcohol	414
16.8	Conclusions	414
17	Nutritional Factors and High-Density Lipoprotein Metabolism	425
	<i>Ernst J. Schaefer, Stefania Lamon-Fava, Bela F. Asztalos</i>	
17.1	Introduction	425
17.2	High Density Lipoprotein Particles and their Metabolism	427
17.3	Effects of Dietary Cholesterol	431

- 17.4 Effects of Dietary Fatty Acids 431
- 17.5 Effects of Exchange of Dietary Fat and Carbohydrate 432
- 17.6 Effects of Diets Restricted in Cholesterol and Saturated Fat 433
- 17.7 Effects of Alcohol Intake 434
- 17.8 Effects of Weight Loss 434
- 17.9 Effects of Exercise 434
- 17.10 Conclusions 435

- V Clinical Aspects of HDL 443**

- 18 HDL and Metabolic Syndrome 445**
Clara Cavalier, Arnold von Eckardstein
- 18.1 Introduction 445
- 18.2 Altered Lipoprotein Metabolism in the Metabolic Syndrome 445
- 18.3 Dysregulated Genes and Proteins of HDL Metabolism 447
- 18.4 Biological Properties of Impaired HDL 452
- 18.5 Treatment of Low HDL-C in Metabolic Syndrome 454
- 18.6 Conclusions 456

- 19 Genetics of High-Density Lipoproteins 465**
Jacques Genest, Zari Dastan, James C. Engert, Michel Marcil
- 19.1 Introduction 465
- 19.2 Background 466
- 19.2.1 Epidemiology of HDL and Risk of Coronary Artery Disease CAD 466
- 19.2.2 HDL Metabolism 467
- 19.3 Genetic Approaches 468
- 19.3.1 Monogenic Disorders, Candidate Genes 468
- 19.3.2 Genome-Wide Studies 476
- 19.3.3 Segregation of HDL-C 478
- 19.3.4 Heritability of HDL-C 479
- 19.3.5 Genetic Association Studies 481
- 19.4 Conclusions 482
- 19.5 Future Considerations 482

- 20 HDL and Atherosclerosis 491**
Philip J. Barter, Kerry-Anne Rye
- 20.1 Introduction 491
- 20.2 HDL and Atherosclerosis: Cause and Effect or an Epiphenomenon? 491
- 20.3 Potential Antiatherogenic Properties of HDL 492
- 20.3.1 HDL and Cholesterol Efflux 492
- 20.3.2 Antioxidant Properties of HDL 493
- 20.3.3 Antiinflammatory Properties of HDL 494
- 20.3.4 Antithrombotic Properties of HDL 495

20.3.5	HDL and Endothelial Repair	495
20.4	HDL Subpopulations and Atherosclerosis	496
20.5	Evidence that Raising the Concentration of HDL Protects against Atherosclerosis	497
20.5.1	Intervention Studies in Animals	497
20.5.2	Intervention Studies in Humans	498
20.6	Conclusions	499
21	Therapeutic Targeting of High-Density Lipoproteins	507
	<i>Daniel J. Rader</i>	
21.1	Introduction	507
21.2	Current Clinical Approaches to Patients with Low HDL-C	507
21.3	Approaches to Raising Levels of HDL-C and/or ApoA-I	508
21.3.1	Increasing HDL/ApoA-I Production and Maturation	508
21.3.2	Inhibiting ApoA-I Catabolism	509
21.3.3	Inhibiting Cholesteryl Ester Transfer	510
21.4	Approaches to Promoting Reverse Cholesterol Transport	511
21.5	Full-Length ApoA-I and ApoA-I Mimetic Peptides	513
21.6	Improving HDL Function	514
21.7	Conclusions	514
	Index	523